Liu and colleagues compared these two different scoring systems in a large cohort of Chinese CRC patients, demonstrating a very high rate of concordance between them despite HER2′s particularly low prevalence in this population (2.9% according to the GEA criteria versus 2.6% according to the HERACLES criteria) [105,106] (Table 1). The gene discussed is ERBB2; the disease is colorectal carcinoma.